Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on May 09, 2007 by Edgar Snyder

Fosamax and Reclast Linked to Heart Problems

Fosamax

Fosamax, a leading osteoporosis drug, has been connected to problems with irregular heart rhythm. Along with Reclast, another bone-building drug, atrial fibrillation developed much higher in test groups that took the medications.

Fosamax is a prescription drug taken daily by postmenopausal women at risk of bone degeneration. By reanalyzing a study made by manufacturer Merck, researchers determined that Fosamax posed a 50 percent greater risk for women to develop atrial fibrillation than those who did not take the drug.

Reclast, an annual intravenous drug used to combat the bone condition known as Paget’s disease, proved even more dangerous. A study funded by manufacturer Novartis showed that the risk of developing irregular heart rhythms was 150 percent greater in patients taking Reclast.

Fosamax is also linked to osteonecrosis of the jaw (ONJ), a rare but serious disease that causes the jaw bone to die. Patients with osteonecrosis of the jaw, also known as Dead Jaw, suffer extreme pain that can often lead to exposed bone in the mouth.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Source: "Unexpected heart problems seen in bone drugs." The Associated Press. May 3, 2007.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet